Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
hepatocell cancer (HCC), VEGF(R) inhibitor vs. anti-PD-(L)1, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 459, 2019 0.85 [0.71; 1.01]
IMbrave-150, 2020 0.58 [0.42; 0.80]
LEAP 002, 2023 0.84 [0.71; 1.00]
ORIENT-32, 2021 0.57 [0.43; 0.75]
0.72 [0.59 ; 0.88 ] CheckMate 459, 2019, IMbrave-150, 2020, LEAP 002, 2023, ORIENT-32, 2021 4 69% 2,609 low not evaluable deaths (OS) (extension)detailed results CheckMate 459, 2019 0.85 [0.72; 1.00]
0.85 [0.72 ; 1.00 ] CheckMate 459, 2019 1 0% 743 NA not evaluable progression or deaths (PFS)detailed results CheckMate 459, 2019 0.93 [0.79; 1.10]
IMbrave-150, 2020 0.59 [0.46; 0.75]
LEAP 002, 2023 0.87 [0.74; 1.03]
0.79 [0.62 ; 1.01 ] CheckMate 459, 2019, IMbrave-150, 2020, LEAP 002, 2023 3 80% 2,038 moderate not evaluable objective responses (ORR)detailed results CheckMate 459, 2019 2.42 [1.48; 3.94]
IMbrave-150, 2020 2.77 [1.62; 4.73]
2.57 [1.79 ; 3.69 ] CheckMate 459, 2019, IMbrave-150, 2020 2 0% 1,244 moderate not evaluable AE (any grade)detailed results IMbrave-150, 2020 0.70 [0.14; 3.50]
LEAP 002, 2023 1.22 [0.59; 2.52]
ORIENT-32, 2021 0.54 [0.28; 1.06]
0.79 [0.45 ; 1.39 ] IMbrave-150, 2020, LEAP 002, 2023, ORIENT-32, 2021 3 24% 1,840 low not evaluable AE (grade 3-4)detailed results IMbrave-150, 2020 1.06 [0.72; 1.55]
LEAP 002, 2023 1.22 [0.92; 1.62]
ORIENT-32, 2021 0.92 [0.63; 1.32]
1.09 [0.90 ; 1.32 ] IMbrave-150, 2020, LEAP 002, 2023, ORIENT-32, 2021 3 0% 1,840 low not evaluable AE leading to death (grade 5)detailed results IMbrave-150, 2020 0.78 [0.33; 1.82]
LEAP 002, 2023 1.34 [0.30; 6.01]
ORIENT-32, 2021 2.95 [0.35; 24.70]
1.01 [0.50 ; 2.03 ] IMbrave-150, 2020, LEAP 002, 2023, ORIENT-32, 2021 3 0% 1,840 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results IMbrave-150, 2020 1.61 [0.88; 2.92]
LEAP 002, 2023 1.84 [1.22; 2.78]
ORIENT-32, 2021 2.51 [1.28; 4.93]
1.89 [1.40 ; 2.56 ] IMbrave-150, 2020, LEAP 002, 2023, ORIENT-32, 2021 3 0% 1,840 low not evaluable SAE (any grade)detailed results IMbrave-150, 2020 1.38 [0.92; 2.07]
1.38 [0.92 ; 2.07 ] IMbrave-150, 2020 1 0% 485 NA not evaluable STRAE (grade 3-4)detailed results CheckMate 459, 2019 0.30 [0.22; 0.41]
0.30 [0.22 ; 0.41 ] CheckMate 459, 2019 1 0% 743 NA not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 459, 2019 0.53 [0.28; 1.00]
0.53 [0.28 ; 1.00 ] CheckMate 459, 2019 1 0% 743 NA not evaluable Abdominal pain AE (grade 3-4)detailed results IMbrave-150, 2020 0.47 [0.12; 1.90]
0.47 [0.12 ; 1.90 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Acute kidney injury AE (grade 3-4)detailed results IMbrave-150, 2020 0.16 [0.02; 1.51]
0.16 [0.02 ; 1.51 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Alopecia AE (grade 3-4)detailed results IMbrave-150, 2020 0.47 [0.01; 23.97]
0.47 [0.01 ; 23.97 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Anaemia AE (grade 3-4)detailed results IMbrave-150, 2020 1.07 [0.32; 3.53]
1.07 [0.32 ; 3.53 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Asthenia AE (grade 3-4)detailed results IMbrave-150, 2020 0.12 [0.01; 1.05]
0.12 [0.01 ; 1.05 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Constipation AE (grade 3-4)detailed results IMbrave-150, 2020 0.47 [0.01; 23.97]
0.47 [0.01 ; 23.97 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Cough AE (grade 3-4)detailed results IMbrave-150, 2020 0.24 [0.01; 7.07]
0.24 [0.01 ; 7.07 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Decreased appetite AE (grade 3-4)detailed results IMbrave-150, 2020 0.31 [0.09; 1.11]
0.31 [0.09 ; 1.11 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Diarrhoea AE (grade 3-4)detailed results IMbrave-150, 2020 0.34 [0.12; 1.01]
0.34 [0.12 ; 1.01 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Dyspepsia AE (grade 3-4)detailed results IMbrave-150, 2020 0.12 [0.01; 2.61]
0.12 [0.01 ; 2.61 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Dyspnoea AE (grade 3-4)detailed results IMbrave-150, 2020 0.63 [0.14; 2.84]
0.63 [0.14 ; 2.84 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Epistaxis AE (grade 3-4)detailed results IMbrave-150, 2020 0.24 [0.01; 7.07]
0.24 [0.01 ; 7.07 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Fatigue AE (grade 3-4)detailed results IMbrave-150, 2020 0.75 [0.24; 2.34]
0.75 [0.24 ; 2.34 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Hypertension AE (grade 3-4)detailed results IMbrave-150, 2020 1.29 [0.73; 2.28]
1.29 [0.73 ; 2.28 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Increase AST AE (grade 3-4)detailed results IMbrave-150, 2020 1.39 [0.61; 3.18]
1.39 [0.61 ; 3.18 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Increased ALT AE (grade 3-4)detailed results IMbrave-150, 2020 2.91 [0.64; 13.19]
2.91 [0.64 ; 13.19 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Infusion-related reaction AE (grade 3-4)detailed results IMbrave-150, 2020 7.75 [0.44; 135.83]
7.75 [0.44 ; 135.83 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Nausea AE (grade 3-4)detailed results IMbrave-150, 2020 0.47 [0.03; 7.61]
0.47 [0.03 ; 7.61 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4)detailed results IMbrave-150, 2020 0.02 [0.00; 0.28]
0.02 [0.00 ; 0.28 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Proteinuria AE (grade 3-4)detailed results IMbrave-150, 2020 4.86 [0.62; 38.30]
4.86 [0.62 ; 38.30 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Pruritus AE (grade 3-4)detailed results IMbrave-150, 2020 0.47 [0.01; 23.97]
0.47 [0.01 ; 23.97 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Pyrexia AE (grade 3-4)detailed results IMbrave-150, 2020 0.95 [0.17; 5.23]
0.95 [0.17 ; 5.23 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Rash AE (grade 3-4)detailed results IMbrave-150, 2020 0.06 [0.00; 1.10]
0.06 [0.00 ; 1.10 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results IMbrave-150, 2020 0.95 [0.23; 3.84]
0.95 [0.23 ; 3.84 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Vomiting AE (grade 3-4)detailed results IMbrave-150, 2020 0.95 [0.09; 10.54]
0.95 [0.09 ; 10.54 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Weight decreased AE (grade 3-4)detailed results IMbrave-150, 2020 0.24 [0.01; 7.07]
0.24 [0.01 ; 7.07 ] IMbrave-150, 2020 1 0% 485 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 05:10 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 234,382,40,132,131,133
- treatments: 776,1069,693,1068,900,1084,1016,1323,985,604,1014,1447,1476,1477,777,1027,1028,669,1564,670,1015,1023,506,908